PL2488194T3 - Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego - Google Patents

Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego

Info

Publication number
PL2488194T3
PL2488194T3 PL10768844.2T PL10768844T PL2488194T3 PL 2488194 T3 PL2488194 T3 PL 2488194T3 PL 10768844 T PL10768844 T PL 10768844T PL 2488194 T3 PL2488194 T3 PL 2488194T3
Authority
PL
Poland
Prior art keywords
neuregulin
treat
nerve injury
cavernous nerve
cavernous
Prior art date
Application number
PL10768844.2T
Other languages
English (en)
Inventor
Anthony O. Caggiano
Anthony J. Bella
Jennifer F. Iaci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2488194T3 publication Critical patent/PL2488194T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/344—Disorders of the penis and the scrotum and erectile dysfuncrion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
PL10768844.2T 2009-10-14 2010-10-14 Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego PL2488194T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25158309P 2009-10-14 2009-10-14
US25216109P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
PL2488194T3 true PL2488194T3 (pl) 2016-11-30

Family

ID=43480932

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17168874T PL3235504T3 (pl) 2009-10-14 2010-10-14 Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego
PL10768844.2T PL2488194T3 (pl) 2009-10-14 2010-10-14 Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego
PL14184157T PL2813238T3 (pl) 2009-10-14 2010-10-14 Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17168874T PL3235504T3 (pl) 2009-10-14 2010-10-14 Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14184157T PL2813238T3 (pl) 2009-10-14 2010-10-14 Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego

Country Status (17)

Country Link
US (3) US9078861B2 (pl)
EP (4) EP3639844A1 (pl)
JP (4) JP5832437B2 (pl)
KR (3) KR102225480B1 (pl)
CN (2) CN104984322B (pl)
AU (1) AU2010306777C1 (pl)
BR (1) BR112012008821A2 (pl)
CA (1) CA2777243A1 (pl)
ES (3) ES2763086T3 (pl)
HK (3) HK1245142A1 (pl)
IL (3) IL219100A0 (pl)
MX (2) MX350374B (pl)
NZ (3) NZ625673A (pl)
PL (3) PL3235504T3 (pl)
RU (3) RU2657770C1 (pl)
WO (1) WO2011047183A2 (pl)
ZA (1) ZA201202638B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3338791T3 (pl) 2008-07-17 2020-04-30 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
EP3639844A1 (en) * 2009-10-14 2020-04-22 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
PT2830645T (pt) * 2012-03-30 2017-11-28 Acorda Therapeutics Inc Neuregulina para utilização no tratamento de lesão do nervo periférico
WO2016122169A1 (ko) * 2015-01-26 2016-08-04 주식회사 바이오코즈글로벌코리아 뉴레귤린을 포함하는 상처 또는 안구건조증의 치료용 약학 조성물
CA3119782A1 (en) * 2018-11-15 2020-05-22 Axogen Corporation Materials and methods for nerve repair with animal-sourced nerve grafts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
US6994856B1 (en) * 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
US6098873A (en) * 1999-02-19 2000-08-08 Pack `N` Stack, Inc. One piece folded and glued container with tabbed columns
WO2001026607A2 (en) * 1999-10-08 2001-04-19 Uab Research Foundation Smdf and ggf neuregulin splice variant isoforms and uses thereof
ATE315582T1 (de) * 2000-02-11 2006-02-15 Proteosys Ag Verwendung von neuregulin-beta als indikator und/oder target
EP1289553B1 (en) * 2000-05-23 2011-07-13 CeNeS Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20040115175A1 (en) * 2000-11-10 2004-06-17 The Board Of Trustees Of The Leland Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US20020168350A1 (en) * 2000-11-10 2002-11-14 Brazelton Timothy R. Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
AU2003276084B2 (en) * 2002-10-10 2009-07-09 Merck Patent Gmbh Bispecific anti-Erb-B antibodies and their use in tumor therapy
JP2006290881A (ja) * 2005-03-15 2006-10-26 Ono Pharmaceut Co Ltd （２ｒ）−２−プロピルオクタン酸を含有してなる運動機能障害の治療剤
CA2658326C (en) * 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
PL3338791T3 (pl) 2008-07-17 2020-04-30 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
EP3639844A1 (en) * 2009-10-14 2020-04-22 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
AU2011289218A1 (en) 2010-08-13 2013-03-14 Georgetown University GGF2 and methods of use
PT2830645T (pt) 2012-03-30 2017-11-28 Acorda Therapeutics Inc Neuregulina para utilização no tratamento de lesão do nervo periférico

Also Published As

Publication number Publication date
EP2488194B1 (en) 2016-01-27
EP3235504B1 (en) 2019-09-18
CN102596225A (zh) 2012-07-18
ES2763086T3 (es) 2020-05-27
ZA201202638B (en) 2015-12-23
EP3235504A1 (en) 2017-10-25
IL261561A (en) 2018-10-31
IL219100A0 (en) 2012-06-28
JP2017114906A (ja) 2017-06-29
JP5832437B2 (ja) 2015-12-16
WO2011047183A3 (en) 2011-11-03
BR112012008821A2 (pt) 2020-09-15
US20110124561A1 (en) 2011-05-26
US20150216936A1 (en) 2015-08-06
EP3639844A9 (en) 2021-03-10
US9078861B2 (en) 2015-07-14
ES2635313T3 (es) 2017-10-03
CA2777243A1 (en) 2011-04-21
AU2010306777B2 (en) 2015-11-19
RU2657770C1 (ru) 2018-06-15
RU2018118552A3 (pl) 2019-11-21
US20180311312A1 (en) 2018-11-01
HK1245142A1 (zh) 2018-08-24
KR20120084765A (ko) 2012-07-30
NZ599499A (en) 2014-06-27
KR20190000378A (ko) 2019-01-02
RU2020106891A (ru) 2021-08-16
AU2010306777A1 (en) 2012-05-17
PL2813238T3 (pl) 2017-11-30
PL3235504T3 (pl) 2020-03-31
IL277220A (en) 2020-10-29
EP2813238B1 (en) 2017-05-03
RU2018118552A (ru) 2019-11-21
KR102225480B1 (ko) 2021-03-08
EP2488194A2 (en) 2012-08-22
HK1174548A1 (zh) 2013-06-14
KR20210025704A (ko) 2021-03-09
ES2569121T3 (es) 2016-05-06
KR101933543B1 (ko) 2018-12-28
JP2013508291A (ja) 2013-03-07
RU2715908C2 (ru) 2020-03-04
WO2011047183A2 (en) 2011-04-21
EP3639844A1 (en) 2020-04-22
AU2010306777C1 (en) 2016-03-17
MX2012004386A (es) 2012-05-23
EP2813238A2 (en) 2014-12-17
IL261561B (en) 2020-09-30
NZ625673A (en) 2015-11-27
CN104984322B (zh) 2020-09-11
JP2016065064A (ja) 2016-04-28
MX350374B (es) 2017-09-04
KR102379876B1 (ko) 2022-03-30
NZ713972A (en) 2017-06-30
HK1204951A1 (en) 2015-12-11
RU2012119603A (ru) 2013-11-20
CN104984322A (zh) 2015-10-21
JP2020015751A (ja) 2020-01-30
CN102596225B (zh) 2015-06-24
JP6109906B2 (ja) 2017-04-05
EP2813238A3 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
HK1217763A1 (zh) 用於治療疾病的方法
PL2501666T3 (pl) Sposób oczyszczania i stabilizacji chloroolefin
EP2282795A4 (en) TREATMENT OF RESPIRATORY DISEASES
ZA201200228B (en) Furazanobenzimidazoles as prodrugs to treat neoplastic or autommune diseases
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL206491A0 (en) Treatment of produce
HK1206632A1 (en) Use of neuregulin to treat peripheral nerve injury
HK1174548A1 (zh) 神經調節蛋白在治療海綿神經損傷中的應用
GB0901456D0 (en) Treatment of psoriasis
GB0921711D0 (en) Use of elastomers to produce gels for treating a wellbore
ZA201202213B (en) Treatment of minerals
ZA201200645B (en) Use of monochlorourea to treat industrial waters
EP2477656A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
GB0914839D0 (en) Treatment of oil
IL200753A0 (en) Treatment of psoriasis
GB0908101D0 (en) Treatment of stress
ZA201108571B (en) Use of pufas to treat nerve damage
ZA201502178B (en) Use of a neuregulin to treat peripheral nerve injury
EP2448411A4 (en) METHOD OF TREATING A NEUROLOGICAL DISORDER
EP2611884A4 (en) MACHINING A HYDROCARBON CIRCULATION
EP2440238A4 (en) Methods of Treatment
GB0900630D0 (en) Methods relating to wool treatment
IL214075A0 (en) Use of pc for treatment follow up
GB0911469D0 (en) Compounds to treat neurodegenerative disease